5 results on '"Cheung, Ramsey"'
Search Results
2. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
- Author
-
Li, Jie, Yang, Hwai-I, Yeh, Ming-Lun, Le, Michael H, Le, An K, Yeo, Yee Hui, Dai, Chia-Yen, Barnett, Scott, Zhang, Jian Q, Huang, Jee-Fu, Trinh, Huy N, Wong, Christopher, Wong, Clifford, Hoang, Joseph K, Cheung, Ramsey, Yu, Ming-Lung, and Nguyen, Mindie H
- Subjects
CHRONIC hepatitis B ,HEPATITIS associated antigen ,CIRRHOSIS of the liver ,FATTY liver ,HEPATOCELLULAR carcinoma ,HEPATITIS ,VIRAL antigens ,RESEARCH ,LIVER tumors ,RESEARCH methodology ,ANTIVIRAL agents ,RETROSPECTIVE studies ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,DISEASE complications - Abstract
Background: Chronic hepatitis B (CHB) and fatty liver (FL) are common, natural history data on concurrent FL and CHB (FL-CHB) are limited. This study aimed to evaluate the effect of FL on cirrhosis, hepatocellular carcinoma (HCC), and hepatitis B surface antigen (HBsAg) seroclearance incidence in CHB patients.Methods: In a retrospective cohort study of 6786 adult CHB patients, we used propensity score matching (PSM) to balance the FL-CHB and non-FL CHB groups. Kaplan-Meier methods were used to compare cumulative cirrhosis, HCC, and HBsAg seroclearance rates between subgroups.Results: Before PSM, compared to non-FL CHB, FL-CHB patients had lower 10-year cumulative rates of cirrhosis, HCC, and a higher HBsAg seroclearance rate. Similar results were found in the matched FL-CHB and non-FL CHB patients, as well as in the antiviral-treated PSM cohort. Cox proportional hazards model indicated FL to remain significantly and strongly associated with lower risk of cirrhosis and HCC (hazard ratio [HR], 0.19 [95% confidence interval {CI}, .12-.33], P < .001 and HR, 0.21 [95% CI, .09-.51], P = .001, respectively) in antiviral-treated patients but not in untreated patients.Conclusions: FL was significantly associated with lower cirrhosis and HCC risk and higher HBsAg seroclearance. Further studies are needed to confirm our funding and investigate the mechanisms underlying the impact of FL on CHB. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
3. Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B.
- Author
-
Le, An K, Yang, Hwai-I, Yeh, Ming-Lun, Jin, Mingjuan, Trinh, Huy N, Henry, Linda, Liu, Anne, Zhang, Jian Q, Li, Jiayi, Wong, Christopher, Wong, Clifford, Cheung, Ramsey, Yu, Ming-Lung, and Nguyen, Mindie H
- Subjects
CIRRHOSIS of the liver ,CLINICAL prediction rules ,RECEIVER operating characteristic curves ,ALANINE aminotransferase ,ASPARTATE aminotransferase ,HEPATITIS B ,DISEASE progression ,RESEARCH ,ANTIVIRAL agents ,MEDICAL cooperation ,EVALUATION research ,RISK assessment ,COMPARATIVE studies ,CHRONIC hepatitis B - Abstract
Background: Chronic hepatitis B (CHB) can progress to cirrhosis, but there are limited noninvasive tools available to estimate cirrhosis risk, including in patients receiving antiviral therapy. This study developed and validated a simple model to assess risk in CHB patients.Methods: The derivation cohort included 3000 CHB patients from 6 centers in the United States, with 52.60% receiving antiviral therapy. External validation was performed for 4552 CHB individuals from similar cohorts in Taiwan, with 21.27% receiving therapy. Cox proportional hazards regression analyses were used to screen predictors and develop the risk score for cirrhosis. Areas under receiver operating characteristic curves (AUROCs) were calculated for predictive value.Results: Sex, age, diabetes, antiviral treatment status/duration, hepatitis B e-antigen, and baseline alanine aminotransferase/aspartate aminotransferase levels were significantly associated with increased cirrhosis risk. A 13-point risk score was developed based on these predictors. The AUROCs for predicting cirrhosis risk were 0.82 at 3 years, 0.85 at 5 years, and 0.89 at 10 years in the derivation cohort, and 0.82, 0.79, and 0.77 in the validation cohort, respectively.Conclusions: We developed and validated a simple cirrhosis prediction model with an independent external cohort that can be applied to both treatment-naive and treatment-experienced CHB patients in diverse settings and locations. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication.
- Author
-
Ogawa, Eiichi, Toyoda, Hidenori, Iio, Etsuko, Jun, Dae Won, Huang, Chung-Feng, Enomoto, Masaru, Hsu, Yao-Chun, Haga, Hiroaki, Iwane, Shinji, Wong, Grace, Lee, Dong Hyun, Tada, Toshifumi, Liu, Chen-Hua, Chuang, Wan-Long, Hayashi, Jun, Cheung, Ramsey, Yasuda, Satoshi, Tseng, Cheng-Hao, Takahashi, Hirokazu, and Tran, Sally
- Subjects
ANTIVIRAL agents ,DEATH ,REPORTING of diseases ,DRUG side effects ,HEPATITIS C ,HEPATOCELLULAR carcinoma ,MULTIVARIATE analysis ,STATISTICS ,DATA analysis ,TERMINATION of treatment ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,EVALUATION - Abstract
Background Cure rates of hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) for patients with active and inactive hepatocellular carcinoma (HCC) may differ, but well-controlled studies are limited. We aimed to evaluate DAA outcomes in a large East Asian HCV/HCC population compared with HCV/non-HCC patients. Methods Using data from the Real-World Evidence from the Asia Liver Consortium (REAL-C) registry (Hong Kong, Japan, South Korea, and Taiwan), we used propensity score matching (PSM) to match HCC and non-HCC (1:1) groups for age, sex, cirrhosis, prior treatment, HCV genotype, treatment regimen, baseline platelet count, HCV RNA, total bilirubin, alanine aminotransferase, and albumin levels to evaluate DAA treatment outcomes in a large population of HCV/HCC compared with HCV/non-HCC patients. Results We included 6081 patients (HCC, n = 465; non-HCC, n = 5 616) treated with interferon-free DAAs. PSM of the entire study population yielded 436 matched pairs with similar baseline characteristics. There was no statistically significant difference in the overall SVR rate of HCC (92.7%) and non-HCC (95.0%) groups. Rates of treatment discontinuation, adverse effects, and death were also similar between HCC and non-HCC groups. Among patients with HCC, those with active HCC had a lower SVR than inactive HCC cases (85.5% vs 93.7%; P =. 03). On multivariable analysis, active HCC, but not inactive HCC, was significantly associated with lower SVR (OR, 0.28; P =.01) when compared with non-HCC. Conclusions Active HCC but not inactive HCC was independently associated with lower SVR compared with non-HCC patients undergoing DAA therapy, although cure rate was still relatively high (85%) in active HCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Prevalence of Viremic Hepatitis C Virus Infection by Age, Race/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999-2016.
- Author
-
Zou, Biyao, Yeo, Yee Hui, Le, Michael Huan, Henry, Linda, Chang, Ellen T, Lok, Anna S, Cheung, Ramsey, and Nguyen, Mindie H
- Subjects
HEPATITIS C virus ,VIRUS diseases ,HEPATITIS C ,HEALTH & Nutrition Examination Survey ,BIRTHPLACES ,ETHNICITY ,AGE distribution ,CROSS-sectional method ,BLACK people ,COGNITION ,HEPATITIS viruses ,RNA ,SURVEYS ,VIREMIA ,DISEASE prevalence ,WHITE people ,LONGITUDINAL method - Abstract
Background: Athough curative therapy is now available for hepatitis C virus (HCV) infection in the United States, it is not clear whether all affected persons have been diagnosed and/or linked to care.Methods: This cross-sectional study utilized data from the National Health and Nutrition Examination Survey (1999-2016) and included 46 465 nonincarcerated and noninstitutionalized participants.Results: Viremic HCV prevalence decreased from 1.32% in 1999-2004 to 0.80% in 2011-2016, although most of the decrease occurred in US-born whites and blacks but not the foreign-born or those born after 1985. In 2011-2016, approximately 1.90 million US adults remained viremic with HCV, and 0.33 million were at higher risk for advanced fibrosis, but only 49.8% were aware of their HCV infection, with higher disease awareness in those with health insurance coverage and US-born persons.Conclusions: The prevalence of viremic HCV has decreased in recent years among US born whites and blacks but not in other race/ethnicities and foreign-born persons and birth cohort born after 1985. Less than half of the viremic population was aware of having HCV infection. Improved HCV screening and linkage to care are needed, especially for the uninsured, foreign-born, birth cohort after 1985 and certain ethnic minorities. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.